MARINOMED BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.8 EUR | -3.40% |
|
-6.23% | -56.16% |
| May. 22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
| May. 21 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 147 | 175.2 | 130.3 | 84.95 | 44.36 | 19.72 | - | - |
| Enterprise Value (EV) 1 | 139.6 | 178.9 | 140.3 | 96.95 | 44.36 | 36.83 | 33.25 | 19.72 |
| P/E ratio | -19.6 x | -29 x | -22 x | -13.1 x | -6.49 x | 41.3 x | 9.31 x | 7.49 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.9 x | 21.6 x | 11.2 x | 7.53 x | 4.83 x | 1.08 x | 0.8 x | 0.65 x |
| EV / Revenue | 22.7 x | 22 x | 12.1 x | 8.6 x | 4.83 x | 2.02 x | 1.35 x | 0.65 x |
| EV / EBITDA | -23.7 x | -33.2 x | -40.1 x | -22.8 x | -9.97 x | 17.9 x | 6.58 x | 2.19 x |
| EV / FCF | - | -16.5 x | - | -17.9 x | -9.53 x | 9.21 x | 3.76 x | 1.97 x |
| FCF Yield | - | -6.07% | - | -5.6% | -10.5% | 10.9% | 26.6% | 50.7% |
| Price to Book | - | 32.7 x | 681 x | -20.4 x | -4.39 x | -2.87 x | -3.47 x | - |
| Nbr of stocks (in thousands) | 1,470 | 1,473 | 1,480 | 1,506 | 1,519 | 1,541 | - | - |
| Reference price 2 | 100.0 | 119.0 | 88.00 | 56.40 | 29.20 | 12.80 | 12.80 | 12.80 |
| Announcement Date | 4/16/20 | 4/14/21 | 4/13/22 | 4/19/23 | 4/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.145 | 8.124 | 11.6 | 11.28 | 9.184 | 18.19 | 24.58 | 30.27 |
| EBITDA 1 | -5.883 | -5.388 | -3.5 | -4.244 | -4.451 | 2.06 | 5.05 | 9.01 |
| EBIT 1 | -6.21 | -5.816 | -4.1 | -4.914 | -5.129 | 1.05 | 4.035 | 8.41 |
| Operating Margin | -101.07% | -71.59% | -35.34% | -43.58% | -55.85% | 5.77% | 16.41% | 27.78% |
| Earnings before Tax (EBT) 1 | -7.212 | -6.007 | -5.7 | -6.391 | -6.791 | 0.51 | 2.27 | 3.24 |
| Net income 1 | -7.216 | -6.01 | -5.9 | -6.398 | -6.795 | 0.47 | 2.09 | 2.59 |
| Net margin | -117.44% | -73.98% | -50.86% | -56.74% | -73.99% | 2.58% | 8.5% | 8.56% |
| EPS 2 | -5.100 | -4.100 | -4.000 | -4.300 | -4.500 | 0.3100 | 1.375 | 1.710 |
| Free Cash Flow 1 | - | -10.85 | - | -5.43 | -4.657 | 4 | 8.85 | 10 |
| FCF margin | - | -133.53% | - | -48.16% | -50.71% | 21.99% | 36% | 33.04% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 194.17% | 175.25% | 110.99% |
| FCF Conversion (Net income) | - | - | - | - | - | 851.06% | 423.44% | 386.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/16/20 | 4/14/21 | 4/13/22 | 4/19/23 | 4/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 3.61 | 10 | 12 | - | 17.1 | 13.5 | - |
| Net Cash position 1 | 7.38 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.6695 x | -2.857 x | -2.829 x | - | 8.306 x | 2.679 x | - |
| Free Cash Flow 1 | - | -10.8 | - | -5.43 | -4.66 | 4 | 8.85 | 10 |
| ROE (net income / shareholders' equity) | - | -74.1% | -211% | - | - | 27.4% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 3.640 | 0.1300 | -2.760 | -6.650 | -4.460 | -3.690 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.34 | 3.96 | - | 0.23 | 0.13 | 6.08 | 2 | 2.55 |
| Capex / Sales | 38.1% | 48.79% | - | 2.02% | 1.4% | 33.42% | 8.14% | 8.42% |
| Announcement Date | 4/16/20 | 4/14/21 | 4/13/22 | 4/19/23 | 4/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.8
EUR
Average target price
63
EUR
Spread / Average Target
+392.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -56.16% | 22.06M | |
| -0.54% | 91.94B | |
| -3.16% | 38.74B | |
| +64.83% | 26.66B | |
| -13.98% | 15.32B | |
| -5.40% | 13.3B | |
| -11.38% | 11.65B | |
| +156.85% | 10.37B | |
| -49.84% | 10.12B | |
| +2.32% | 9.06B |
- Stock Market
- Equities
- MARI Stock
- Financials Marinomed Biotech AG
